Literature DB >> 32350671

MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy.

Valentina Pegoraro1, Paola Cudia1, Alfonc Baba1, Corrado Angelini2.   

Abstract

MiR-1 and myostatin are markers for muscle growth and regeneration. Myostatin has a key role in the regulation of muscle mass. Myotonic dystrophy type 1(DM1) patients have a disease-specific serum miRNA profile characterized by upregulation of miR-1, miR-206, miR-133a, and miR-133b (myomiRNAs).This study aims to evaluate the possible utility of myomiRs and myostatin as biomarkers of rehabilitation efficacy in DM1, supporting clinical outcomes that are often variable and related to the patient's clinical condition.In 9 genetically proven DM1 patients, we collected biological samples before (T0) and after (T1) exercise rehabilitation training as biological measurement. We measured serum myomiRNAs by qRT-PCR and myostatin by ELISA test. The clinical outcomes measures that we utilized during a 3-6 week rehabilitation controlled aerobic exercise period were the 6-min walking test (6MWT) that increased significantly of 53.5 m (p < 0.0004) and the 10-m walk test (10MWT) that decreased of 1.38 s.We observed, after physical rehabilitation, a significant downregulation of myomiRNAs and myostatin that occurred in parallel with the improvement of clinical functional outcome measures assessed as endurance and gait speed, respectively.The modulation of biomarkers may reflect muscle regeneration and increase muscle mass after aerobic exercise. miRNAs and myostatin might be considered as circulating biomarkers of DM1 rehabilitation. The efficacy of physical rehabilitation in counteracting molecular pathways responsible for muscle atrophy and disease progression and the role of these biomarkers in DM1 and other neuromuscular diseases warrant further investigation.

Entities:  

Keywords:  Circulating myomiRNAs; DM1; DM1 physical rehabilitation; Myostatin; c-FES

Mesh:

Substances:

Year:  2020        PMID: 32350671     DOI: 10.1007/s10072-020-04409-2

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  3 in total

Review 1.  The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I.

Authors:  Emma Koehorst; Alfonsina Ballester-Lopez; Virginia Arechavala-Gomeza; Alicia Martínez-Piñeiro; Gisela Nogales-Gadea
Journal:  J Clin Med       Date:  2020-12-04       Impact factor: 4.241

Review 2.  Epigenetics of Myotonic Dystrophies: A Minireview.

Authors:  Virginia Veronica Visconti; Federica Centofanti; Simona Fittipaldi; Elisa Macrì; Giuseppe Novelli; Annalisa Botta
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

3.  miR-223-3p and miR-24-3p as novel serum-based biomarkers for myotonic dystrophy type 1.

Authors:  Demetris Koutalianos; Andrie Koutsoulidou; Chrystalla Mytidou; Andrea C Kakouri; Anastasis Oulas; Marios Tomazou; Tassos C Kyriakides; Marianna Prokopi; Konstantinos Kapnisis; Nikoletta Nikolenko; Chris Turner; Anna Lusakowska; Katarzyna Janiszewska; George K Papadimas; Constantinos Papadopoulos; Evangelia Kararizou; George M Spyrou; Geneviève Gourdon; Eleni Zamba Papanicolaou; Grainne Gorman; Andreas Anayiotos; Hanns Lochmüller; Leonidas A Phylactou
Journal:  Mol Ther Methods Clin Dev       Date:  2021-09-14       Impact factor: 6.698

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.